"Simeprevir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Oral HCV-PROTEASE INHIBITOR effective against hepatitis C virus (HCV) serine protease NS3/4A. It is used in the treatment of chronic hepatitis C (Antivirals) genotype 1 infection in adults with compensated liver disease, including CIRRHOSIS.
| Descriptor ID |
D000069616
|
| MeSH Number(s) |
D02.886.590.700.700 D03.633.300.819
|
| Concept/Terms |
Simeprevir- Simeprevir
- N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide
TMC 435350- TMC 435350
- 435350, TMC
- TMC435350
- TMC-435350
TMC 435- TMC 435
- 435, TMC
- TMC435
- TMC-435
|
Below are MeSH descriptors whose meaning is more general than "Simeprevir".
Below are MeSH descriptors whose meaning is more specific than "Simeprevir".
This graph shows the total number of publications written about "Simeprevir" by people in this website by year, and whether "Simeprevir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Simeprevir" by people in Profiles.
-
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy. Am J Gastroenterol. 2016 Dec; 111(12):1854-1856.
-
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Am J Gastroenterol. 2016 Feb; 111(2):250-60.
-
Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis. 2015 Oct 15; 61(8):1304-6.
-
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy. Hepatology. 2014 Jul; 60(1):12-4.